← back to search

Robin Filshie

St Vincent Hospital ·
Area of research
Hematology · Genetics
Research interest
Research interests include Chronic Lymphocytic Leukemia Research, Chronic Myeloid Leukemia Treatments, Acute Lymphoblastic Leukemia research, and Acute Myeloid Leukemia Research.
h-index
24
citations
3,306
works
85
NIH funding
primary concept
Medicine
email

Recent publications

Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study
Blood 2024cited by 21position: middledoi
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes
American Journal of Hematology 2022cited by 74position: middledoi
Venetoclax and Azacitidine in the Treatment of Patients with Relapsed/Refractory Myelodysplastic Syndrome
Blood 2021cited by 17position: middledoi
A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis
Blood 2016cited by 62position: middledoi
Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14
Haematologica 2016cited by 55position: middledoi
Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial
The Lancet Haematology 2015cited by 166position: middledoi
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets
Blood 2014cited by 102position: middledoi
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)
Blood 2012cited by 339position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Mark Hertzberg · Australasian Leukaemia and Lymphoma Group4 papers (2012–2016)John Taper · Nepean Hospital4 papers (2012–2016)Andrew Grigg · University of Southampton4 papers (2012–2016)John Reynolds · Monash Medical Centre3 papers (2012–2024)John F. Seymour · Peter MacCallum Cancer Centre3 papers (2012–2016)Peter Browett · University of Auckland3 papers (2012–2024)Jacqueline S. Garcia · Boston University2 papers (2021–2022)John J. Moore · UNSW Sydney2 papers (2012–2015)David T Yeung · The University of Adelaide2 papers (2014–2024)Harry Iland · The University of Sydney2 papers (2012–2015)Andrew M. Brunner · Harvard University2 papers (2021–2022)Susan Branford · Royal Adelaide Hospital2 papers (2014–2024) · 2 papers (2012–2015)Uma Borate · Lantheus Medical Imaging (United States)2 papers (2021–2022)David Hoffman · AbbVie (United States)2 papers (2021–2022)Ashish Bajel · The University of Melbourne2 papers (2021–2022) · 2 papers (2012–2015) · 2 papers (2012–2015)Jeff Szer · The Royal Melbourne Hospital2 papers (2012–2015)Daniel A. Pollyea · University of Colorado Boulder2 papers (2021–2022)